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Abstract
Background: Approximately 30% of Persian cats have a c.10063C > A variant in polycystin 1 (PKD1) homolog
causing autosomal dominant polycystic kidney disease (ADPKD). The variant is lethal in utero when in the
homozygous state and is the only ADPKD variant known in cats. Affected cats have a wide range of progression and
disease severity. However, cats are an overlooked biomedical model and have not been used to test therapeutics and
diets that may support human clinical trials. To reinvigorate the cat as a large animal model for ADPKD, the efficacy of
imaging modalities was evaluated and estimates of kidney and fractional cystic volumes (FCV) determined.
Methods: Three imaging modalities, ultrasonography, computed tomography (CT), and magnetic resonance imaging
examined variation in disease presentation and disease progression in 11 felines with ADPKD. Imaging data
was compared to well-known biomarkers for chronic kidney disease and glomerular filtration rate. Total
kidney volume, total cystic volume, and FCV were determined for the first time in ADPKD cats. Two cats had
follow-up examinations to evaluate progression.
Results: FCV measurements were feasible in cats. CT was a rapid and an efficient modality for evaluating
therapeutic effects that cause alterations in kidney volume and/or FCV. Biomarkers, including glomerular filtration rate
and creatinine, were not predictive for disease progression in feline ADPKD. The wide variation in cystic presentation
suggested genetic modifiers likely influence disease progression in cats. All imaging modalities had comparable
resolutions to those acquired for humans, and software used for kidney and cystic volume estimates in humans proved
useful for cats.
Conclusions: Routine imaging protocols used in veterinary medicine are as robust and efficient for evaluating ADPKD
in cats as those used in human medicine. Cats can be identified as fast and slow progressors, thus, could assist with
genetic modifier discovery. Software to measure kidney and cystic volume in human ADPKD kidney studies
is applicable and efficient in cats. The longer life and larger kidney size span than rodents, similar genetics,
disease presentation and progression as humans suggest cats are an efficient biomedical model for evaluation
of ADPKD therapeutics.
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is one of the most commonly inherited disorders in
humans, with an estimated prevalence of 1:400 to 1:1,
000 [1]. ADPKD is the fourth most common cause of
renal replacement therapy (i.e., dialysis or transplant)
[2–4] and is generally diagnosed by imaging of the kid-
ney using ultrasonography (US), computed tomography
(CT), or magnetic resonance imaging (MRI). For
ADPKD, approximately 75–85% of cases are caused by
variants in PKD1, which encodes the protein known as
polycystin-1 [5–7]. Most human families with ADPKD
have novel variants and over 1,273 causal variants for
PKD1 are catalogued in the Autosomal Dominant Poly-
cystic Kidney Disease Mutation Database: PKDB [8]. Be-
cause of this genetic heterogeneity, cohorts with the
same PKD1 variant or cohorts with the same genetic
backgrounds are limited in humans, which inhibits the
power of studies focused on genetic modifiers that
would influence interfamilial, intrafamilial and sex differ-
ences in disease progression and responses to therapeu-
tics. Genetic screening is also complicated in humans
since PKD1 includes 46 exons, has a large, ~ 14 kb
mRNA [9] spanning a 47.2 kb genomic region, and six
pseudogenes are present in the human genome [10, 11].
ADPKD is widely recognized as the most commonly
inherited renal disease in the domestic cat, specifically
cats of the Persian breed [12–16]. The feline PKD1 vari-
ant (c.10063C > A) causes a stop codon at position 3284
in exon 29 (C3284X) [17] and is the only variant causing
ADPKD in cats known to date. This variant is found in
Persian-related breeds as well [17–19]. Hepatic and pan-
creatic cysts are present in some cats with ADPKD [14,
16, 20], however, hypertension is noted to be minor [21],
and other vascular or systemic complications are not
documented. Although many ADPKD cats remain sub-
clinical through-out their lives, some show rapid disease
progression, developing chronic kidney disease (CKD)
secondary to ADPKD, and succumb to disease within 7
years of life or earlier, which is only mid-life for a cat
[16, 22]. These younger cats that succumb to disease
have consistent disease progressing to humans who have
truncating PKD1 variants [5]. Cats should be instrumen-
tal for identifying genetic modifiers of cystic progression
and for deciphering variation in therapeutic responses
since the solitary causal variant and control of the gen-
etic background via colony of ADPKD cats will reduce
variables in the analyses.
US, CT, and MRI are commonly used imaging modal-
ities to evaluate disease progression and the therapeutic
efficacy in humans with ADPKD [23], however, detailed
and comparative imaging in feline ADPKD using different
modalities is limited. US is routinely used to diagnose fe-
line ADPKD, however, a study assessing the progression
of the disease over time (approximately 1 year) showed an
apparent improvement in a small number of cats [24],
thus, the accuracy of US is questionable. In humans, US is
used to screen ADPKD-suspected patients to follow
changes over long periods of time, while CT and MRI are
used to quantify changes in kidney parenchyma over
shorter intervals [23]. In rodents, imaging accurately re-
flects kidney volumes, however, due to the small sizes of
rodent kidneys, accurate evaluations of fractional cyst vol-
ume (FCV) are difficult and limited without the use of
ultra-high field MRI (7 T and above) [25]. CT and MRI are
the routine modalities used to evaluate the interventional
efficacy of newly developed drugs in humans. MRI has not
been used to evaluate ADPKD in cats, thus, baseline im-
aging studies could support the cats’ role for evaluating
therapeutics.
Three imaging modalities, US, CT, and MRI, are used
to examine variation in disease presentation and disease
progression in feline ADPKD. Imaging was compared to
well-known biomarkers for CKD, such as urine specific
gravity (USG), blood urea nitrogen (BUN), serum cre-
atinine (sCr), glomerular filtration rate (GFR) and sym-
metric dimethylarginine (SDMA), which is a novel
biomarker for feline CKD at the earlier stage [26]. Total
kidney volume (TKV), total cystic volume (TCV) and
FCV were determined for the first time in ADPKD cats,
demonstrating the wide variation in disease presentation,
the potential identification of rapid and slow progression




The cats represented an ADPKD cat colony housed at
the University of Missouri (MU), which has been main-
tained for over 20 years. Five Persian cats with ADPKD
were originally donated by private owners to establish
the colony. All animal procedures were conducted in ac-
cordance with the National Research Council Guide for
the Care and Use of Laboratory Animals and were ap-
proved by the MU Animal Care and Use Committee
(protocol #8787). Cat housing and husbandry was over-
seen by MU Office of Animal Research. No cats were
euthanized as part of this study. However, cats were eu-
thanized by barbiturate overdose after sedation as dic-
tated by poor health (renal failure). All cats were
genotyped for the PKD1 c.10063C > A that causes feline
ADPKD (data not shown) [17, 27]. Diagnostic imaging
studies were performed at MU during normal clinic
hours (8:00 am – 6:00 pm) from November 2016 to May
2017, for the initial imaging, and June 2018 for the
follow-up CT and MRI imaging of two cats. Cats were
fasted for at least 12 h prior to diagnostic imaging. At
the time of sedation for imaging, blood was collected by
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jugular venipuncture for a complete blood count, serum
chemistry including BUN, sCr, SDMA. Urine was col-
lected for urinalysis via cystocentesis using ultrasound
guidance.
Ultrasonography
US examinations were performed using an 8MHz
micro-convex transducer on a dedicated ultrasound unit
(Logiq 9, GE Healthcare, Wauwatosa, WI, USA). Each
kidney was scanned in sagittal and transverse planes by
either a first-year veterinary radiology resident (K.L.S.)
or a board-certified veterinary radiologist (J.S.M.). The
length was measured, using internal digital calipers, as
the longest point between the cranial and caudal poles
in the sagittal plane. Width and height were measured in
the transverse plane. TKV was calculated using the pro-
late ellipsoid formula [28].
Glomerular filtration rate
GFRs were determined on the same day as the US im-
aging. Approximately 3 mCi of 99mTc-diethylenetriamine-
pentaacetic acid was administered intravenously. Images
were obtained using a gamma camera (Equistand II, Diag-
nostic Services, Middlesex, NJ.) with a low energy all-
purpose collimator and using a 256 × 256 matrix. The
GFR was calculated for each kidney by a single observer
(K.L.S.), using Mirage software and a previously described
method for scintigraphic uptake [29].
Magnetic resonance imaging
MRI was performed using a 3 T unit (Vantage Titan 3 T,
Canon Medical Systems, Tustin, CA, USA) and a trans-
mit/receive coil. Scans obtained included dorsal T2 (TR
2469–5675, TE 120) weighted imaging (T2WI) with 2
mm slices, a 0.2 mm interspace gap, matrix = 320 × 320–
352, and number of acquisitions = 1–3. The scans were
performed using respiratory gating to eliminate respira-
tory motion.
Computed tomography
CT scans were performed using a third generation 64
slice instrument (Aquillion 64, Canon Medical Systems,
Tustin, CA, USA) under the same anesthetic event as
the MRI scan. Follow-up imaging was performed for two
cats at 12 months and 15 months, which were thought
to have fast and slow cyst progression (i.e., high and low
FCV at the youngest age), respectively.
Calculation of imaging parameters from CT and MRI data
TKVs were calculated from US as described above. TKVs
as determined by CT and MRI was measured using a
planimetry method with Fiji software common to veter-
inary practice [30]. To determine the area per slice, the
outline of the kidney was traced by free-hand by a single
investigator (K.L.S.) on each contiguous slice. Total vol-
umes of the kidneys were obtained by summing the
areas of the slices and multiplying by slice thickness.
TKV and TCV were also calculated by a single analyst
(M.E.E.) using the minimal interaction rapid organ seg-
mentation (MIROS) method [31]. Cyst progression rate
was predicted from the FCV per months (age) and from
follow-up CT and MRI for two cats at 12 months and
15months as described above.
Statistical analysis
Means and standard deviations were calculated for 11
ADPKD cats for variables imaging indexes. All statistical
analyses were performed using R software (version 3.3.3;
R Foundation for Statistical Computing, Vienna, Austria).
Comparisons of kidney volumes between male and female
cats were analyzed using Mann–Whitney U test. The
Spearman’s rank correlation test was used for the correl-
ation analyses of imaging parameters and clinical data
such as age, body weight and serum biomarkers. Kendall’s
coefficient of concordance was calculated to evaluate the
reliability between or among each modality. High agree-
ment is indicated when Kendall’s coefficient of concord-
ance (W) is higher than 0.75. P values < 0.05 were
considered statistically significant. Data are expressed as
mean ± standard deviation (SD).
Results
Signalment and renal biomarkers
Thirteen cats were examined, 11 cats were positive for
the feline PKD1 variant (c.10063C > A) (Table 1). The
two normal cats were one male (17.88 months, 4.9 kg)
and one female (15.12 months, 3.0 kg). All 13 cats had
normal physical examinations at the time of imaging, in-
cluding normal kidneys determined by palpation. A ma-
jority of cats were within normal limits for biomarkers,
including USG, BUN, sCr, SDMA, and GFR (Table 1).
Expected correlations were identified within the serum
biomarkers including a positive correlation for SDMA
and sCr (r = 0.88, p < 0.001), a positive correlation for
sCr with BUN (r = 0.78, p = 0.004), and a positive correl-
ation for SDMA with BUN (r = 0.61, p = 0.047).
The oldest ADPKD cat (female; 8.1 years, Case 2) had
an SDMA level of 15 μg/dL, sCr level of 1.6 mg/dL, and
the lowest USG of 1.028. This cat was categorized as fe-
line CKD Stage 2 based on the guidelines for feline CKD
(International Renal interest Society; IRIS staging of
CKD modified 2016; http://www.iris-kidney.com/guide-
lines/staging.html, accessed May 13, 2018). This cat was
re-evaluated after 15 months and had mildly elevated
levels of sCr (2.4 mg/dL) and BUN (36mg/dL) and lower
USG (1.015) indicating advancing renal failure. At 19
months after the initial imaging, this cat rapidly declined
within 2 weeks, reducing from normal weight of 3.9 kg
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to 2.7 kg and was euthanized due to end stage renal dis-
ease. All other APDKD cats had cysts and were classified
as feline CKD Stage 1.
Glomerular flow rate
The two normal cats had GFRs of 2.66 and 2.97 ml/min/
kg. The majority of ADPKD affected cats had normal
average GFRs, ranging from 2.15–3.95 ml/min/kg. Three
cats showed below normal GFRs of 2.30, 2.18 and 2.15
ml/min/kg (Table 1). GFR had no suggested correlations
with any biomarkers. GFR was not correlated with the
TKV, regardless of modality used or the method of esti-
mation of TKV (Additional file 1: Table S1). In addition,
no correlation was identified between GFR and age of
the cats (r = 0.1, p = 0.78) (Additional file 1: Figure S1).
Imaging
The normal cats did not have incidental cysts. A major-
ity of cysts in the ADPKD cats were located in the cor-
tex or at the corticomedullary junction, however, some
cysts were located in the medulla, which is consistent
with previous reports for feline ADPKD [32]. All
ADPKD cats had bilateral, multiple cysts but with vari-
ation in number and size (Fig. 1). Simple cysts were
homogeneously hyperintense on T2WI MRI, however,
some cats showed some T2-hypointense foci (Fig. 1).
Kidney volume estimates
Individual kidney volumes and TKVs were determined
for each cat using three imaging modalities (Table 2,
Additional file 1: Table S2). Males consistently had
larger kidneys than females. The mean TKV ranged
from 45.32 ± 13.50 ml for US to 69.39 ± 12.08 ml for
planimetric MRI estimates. US-based volume esti-
mates using the ellipsoid method were consistently
the lowest estimated TKVs and MRI-based estimates
were consistently the highest, especially the planimet-
ric method for MRI. The TKV estimations for the
two different methods were highly correlated within
the CT and MRI modalities (r = 0.95–1, p < 0.01). US
estimates were more strongly correlated with CT
(MIROS) (r = 0.84, p < 0.01) than MRI (Additional file
1: Table S3). The ranks of the TKVs were consistent
between planimetry and MIROS methods for MRI
(W = 1, p = 0.042), and were fairly consistent between
the planimetry and MIROS methods for CT (W =
0.92, p = 0.048) (Additional file 1: Table S4). The four
cats with the lowest kidney volumes, including con-
trols, were ranked more consistently across modalities
than the cats with the larger kidney volumes. The
cats with the three largest TKVs were ranked consist-
ently between US and both MRI methods, although
the US estimates were ~ 30% lower in volume. Ap-
proximately one-year post-imaging, TKVs for case 4
and case 5 were estimated by the water displacement
Table 1 Signalment and renal biomarker data of ADPKD and control cats
Cat ID Agea (mo) Weight (kg) Sex SDMA (0–14) sCr (0.5–2.2) BUN (19–35) USG (1.035<) GFR (2.5<)
Case 1 46.44 4.3 M 9 1.1 16 1.051 2.3
Case 2 97.08 3.9 F 15 1.6 24 1.028 2.78
Case 2b ~ 112 3.9 F NA 2.4 36 1.015 NA
Case 2b ~ 116 2.7 F NA 11.9 260 NA NA
Case 3 19.44 3.6 F 12 1.2 24 1.055 3.95
Case 3b ~ 32 ~ 3.6 F 14 1.3 24 1.046 NA
Case 4 33.72 3.4 F 9 1.2 22 1.06 2.6
Case 5 46.08 5.5 M 12 1.2 19 1.062 2.18
Case 6 47.04 4.2 M 9 0.9 13 1.06 3.12
Case 6b ~ 63 ~ 4.2 M 8 0.7 18 1.062
Case 7 33.36 5.2 F 9 1 18 1.064 2.15
Case 8 22.92 6.0 M 8 0.9 14 1.06 2.83
Case 9 58.68 4.7 M 4 0.9 16 1.066 3.3
Case 10 15.12 4.1 F 8 0.9 21 1.08 3.28
Case 11 16.44 4.8 M 8 0.9 13 1.056 2.64
mean ± SD 39.67 ± 23.89 4.52 ± 0.81 6F:7M 9.36 ± 2.84 1.07 ± 0.22 18.18 ± 4.14 1.058 ± 0.013 2.83 ± 0.55
Control 1 15.12 3 M 4 0.9 17 1.063 2.66
Control 2 17.88 4.86 F 8 0.9 24 1.066 2.97
aAge at time of imaging. M Male, F Female, SDMA Symmetric dimethylarginine (ug/dL), sCr serum creatinine (mg/dL), BUN Blood urea nitrogen (mg/dL), USG Urine
specific gravity, GFR Glomerular filtration rate (ml/min/kg), NA Not available. bFollow-up values were not used to calculate means ± SD
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method (data not shown) and were 26.5 and 51.2 ml,
respectively (Additional file 1: Fig. S2).
Cystic index
TCVs were calculated using the MIROS method for both
CT (n = 11) and MRI (n = 9) (Table 3, Additional file 1:
Table S3). CT-based TCV ranged from 0.16 to 16.30 ml
(mean = 5.79 ± 5.29 ml). MRI-based TCV ranged from
3.12 to 22.86 ml (mean = 9.83 ± 7.39 ml), ~ 70% larger
than CT-based estimates. CT-based FCV ranged 0.63 to
28.22% (mean = 9.33 ± 8.37%). MRI-based FCV ranged
from 6.18 to 44.64% (mean = 16.37 ± 14.06%), ~ 75% lar-
ger than the CT estimates. Differences between right
and left kidney FCV ranged from 0.03 to 12.32% based
on CT imaging and from 0.71 to 17.29% for MRI (Table
3). The average difference in FCV between left and right
kidneys was 4.57% for CT-based estimates and 6.96% for
MRI-based estimates. In comparisons to biomarkers,
concentrations of sCr were mildly associated with FCVs
(CT- or MRI-based) (r = 0.67, p = 0.02; r = 0.65, p = 0.06,
respectively) and TCV (MRI-based) (r = 0.67, p = 0.05).
Additionally, concentration of BUN was mildly associ-
ated with MRI-based TCV (r = 0.77, p = 0.02). GFR was
not significantly correlated with TKV, TCV or FCV
(Additional file 1: Table S1).
TKV, TCV and FCV progression
FCV increased approximately 0.04 to 1.08% per month
based on CT imaging and 0.16 to 1.84% per month
based on MRI. The scatter plots for cat age versus FCV
suggests cystic growth rate is linear during CKD Stage 1
of disease in cats (Fig. 2). However, one cat was a sug-
gested “outlier” for cystic volume as this young female
cat (Case 3, 19.45 months) had the second largest TCV
and FCV (MRI and CT), or also, could also be consid-
ered as the high end of a range in disease progression.
Removal of this “outlier” cat improved correlations (r >
0.8, p < 0.05) for both MRI-based and CT-based TCV
and FCV estimates (Fig. 2).
The general cyst progression rate (FCV per month)
was an average of 0.19% per month (CT-based), if pro-
gression is considered linear, and 0.29% per month
(MRI-based), when excluding the fastest outlier. The fast
progression “outlier” cat (Case 3) had an expected FCV
per month of 1.08% by CT and 1.84% by MRI. Case 6
was a slowly progressing cat with an expected FCV per
month of 0.10% by CT and 0.16% by MRI. These two
cats were re-evaluated after 12.6 and 15.0 months, re-
spectively (Fig. 3, Table 4). TKV and TCV increased
more drastically in the fast progression cat versus the
slow progression cat and FCV increases were within the
predicted estimates. However, the FCV increase based
on MRI was counter intuitive as the estimate was 78.1%
in the slow progression cat and only 33.62% for the fast
progression cat. Also, the percent increase of FCV was
similar between the two cats, 47.69 and 47.19% as esti-
mated by CT. Based on the follow-up MRI (MIROS
method), case 6 with the lowest FCV did not have a
drastic increase in TKV (from 62.85 to 64.36 ml), how-
ever, had an 82.4% increase in TCV (4.71–8.59 ml) and a
78.1% increase of FCV (7.49–13.35%). Interestingly, per-
centage of monthly increase during the follow-up inter-
val are within 9.8–11.9% in the both of cats, based on
the both CT and MRI-based measurements.
Fig. 1 T2-weighted MR imaging of ADPKD cats. Cysts in ADPKD
positive cats were T2-hyperintense. a T2-weighted imaging of 1.6
years old cat (Case 3) that shows high FCV. b T2WI of 1.9 years old
cat (Case 8) that shows low FCV. c T2-weighted imaging of 4.9 years
old cat (Case 9). T2-hypointense foci are seen, suggesting the presence
of T2-hypointense material such as hemorrhage. This finding was
observed in several cats
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Each estimate of TCV, FCV, and FCV per month were
significantly correlated between modalities (i.e., CT-based
and MRI-based) (r = 0.95–0.98, p < 0.01) (Additional file 1:
Table S3). The rank of TCV was the same between the
modalities except for one cat. Kendall’s coefficient of con-
cordance showed W= 0.89 (p = 0.075). The rank of FCV
showed W= 0.82 (p = 0.11) with Kendall’s coefficient of
concordance (Additional file 1: Table S4).
Discussion
ADPKD is caused by PKD1 variants and is a common
genetic and life-threatening disease for both humans and
domestic cats. Although a variety of rodent models sup-
port PKD research, none support long-term trials of
therapeutics. ADPKD domestic cats have a stop codon
in exon 46, disrupting ~ 30% of polycystin-1 [17]. The
disease is autosomal dominant, the homozygous state is
Table 2 Summary of ADPKD cat individual and total kidney volumes
Volume Modality
(method)
All (n = 11)* Male (n = 6) Female (n = 5)* P-value
Mean SD Mean SD Mean SD
TKV US (Ellipsoid) 45.32 13.50 51.49 6.87 37.92 16.46 0.2222
CT (Planimetry) 56.52 17.79 66.63 9.72 44.38 18.33 0.0303
CT (MIROS) 58.83 19.03 69.37 11.70 46.17 19.16 0.1255
MRI (Planimetry) 69.37 11.30 71.06 12.99 66.00 7.96 NA
MRI (MIROS) 62.91 10.36 64.71 11.41 59.32 8.63 NA
RKV US (Ellipsoid) 21.91 6.93 25.72 4.64 17.33 6.72 0.08225
CT (Planimetry) 27.54 9.87 34.07 6.06 19.71 7.55 0.008658
CT (MIROS) 28.59 10.56 35.27 7.44 20.57 7.89 0.01732
MRI (Planimetry) 34.67 7.81 36.90 7.65 30.21 7.28 NA
MRI (MIROS) 30.89 7.08 33.35 6.71 25.96 5.79 NA
LKV US (Ellipsoid) 23.41 7.15 25.77 2.95 20.59 9.93 0.9307
CT (Planimetry) 28.97 8.82 32.56 4.52 24.67 11.25 0.329
CT (MIROS) 30.24 9.40 34.10 5.15 25.61 11.77 0.1775
MRI (Planimetry) 34.71 4.99 34.16 6.14 35.80 1.66 NA
MRI (MIROS) 32.03 4.57 33.35 25.56 33.36 32.79 NA
TKV Total kidney volume, RKV Right kidney volume, LKV Left kidney volume, NA Not applicable. *all n = 9 for MRI, female n = 3 for MRI.
Table 3 TCV and FCV estimated from CT and MRI in ADPKD cats
CT MRI
TCV FCV (%) FCV/Mo (%) TCV FCV (%) FCV/Mo (%)
Cat ID Agea (mo) Right Left Total Right Left Total Right Left Total Right Left Total Right Left Total Right Left Total
Case 1 46.44 1.82 1.94 3.76 6.00 7.66 6.75 0.13 0.16 0.15 3.35 2.94 6.29 11.36 12.07 11.68 0.24 0.26 0.25
Case 2 97.08 7.55 8.75 16.30 33.65 24.76 28.22 0.35 0.26 0.29 10.04 12.82 22.86 49.26 41.58 44.64 0.51 0.43 0.46
Case 3 19.44 3.49 9.13 12.63 13.93 26.25 21.09 0.72 1.35 1.08 6.68 14.24 20.92 26.13 43.43 35.85 1.34 2.23 1.84
Case 4 33.72 0.91 0.90 1.81 7.09 7.18 7.13 0.21 0.21 0.21 NA
Case 5 46.08 1.82 3.66 5.48 4.91 10.05 7.46 0.11 0.22 0.16 2.86 4.77 7.63 8.29 14.54 11.34 0.18 0.32 0.25
Case 6 47.04 0.29 2.52 2.82 1.18 7.74 4.91 0.03 0.16 0.10 0.72 3.99 4.71 2.47 11.82 7.49 0.05 0.25 0.16
Case 7 33.36 0.91 1.64 2.55 3.00 5.06 4.06 0.09 0.15 0.12 1.74 2.51 4.25 5.45 6.89 6.21 0.16 0.21 0.19
Case 8 22.92 2.87 0.37 3.24 7.53 1.09 4.50 0.33 0.05 0.20 5.23 0.69 5.92 13.09 2.05 8.05 0.57 0.09 0.35
Case 9 58.68 6.77 5.14 11.91 14.52 12.60 13.62 0.25 0.21 0.23 7.18 5.58 12.76 17.05 14.62 15.90 0.29 0.25 0.27
Case 10 15.12 0.07 0.08 0.16 0.61 0.64 0.63 0.04 0.04 0.04 NA
Case 11 16.44 0.60 2.43 3.03 1.71 6.82 4.30 0.10 0.41 0.26 0.73 2.39 3.12 2.92 9.38 6.18 0.18 0.57 0.38
Average 39.67 2.46 3.32 5.79 8.56 9.99 9.33 0.21 0.29 0.26 4.28 5.55 9.83 15.11 17.28 16.37 0.39 0.51 0.46
SD 23.89 2.55 3.13 5.29 9.55 8.42 8.37 0.20 0.36 0.28 3.22 4.76 7.39 14.82 14.78 14.06 0.39 0.66 0.53
aAge in months at the initial scan. NA: Not available
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lethal in utero, and cysts develop prior 8 months of age.
Thus, this cat models mimics the human condition gen-
etically. However, little is known about the changes in
kidney imaging parameters in ADPKD cats, especially
TKV, TCV, and FCV.
The rate and extent of cystic progression has not been
examined in cats, although generally, cysts worsen as the
cat ages. The average life span of cats is ~ 13–17 years of
age and many die of CKD [33, 34]. One of the factors
leading to the discovery of ADPKD was early CKD as
cats were dying at 3–4 years old. However, many cats
with ADPKD live a normal life span. Thus, the variation
in disease severity and rate of progression is recognized
but undocumented. Imaging is required to determine
disease severity and to monitor progression even though
a genetic test exists for feline ADPKD [17, 27]. The
range in severity suggests additional genetic and non-
genetic factors influence disease progression.
Eleven ADPKD cats were examined by different mo-
dalities to quantify the variation in the cats and to com-
pare imaging modalities. Ten of eleven cats had no
suggestion of renal compromise other than the presence
of cysts, thus renal biomarkers, including SDMA, sCr
and BUN, are not predictive risk indicators of feline
ADPKD and disease severity. GFR was also not indica-
tive of kidney disease in the ADPKD cats. Significant
parenchymal loss is likely to be required before abnor-
mal GFRs are observed in APDKD cats [32]. The GFRs
were within normal limits or low for the ADPKD cats,
including the oldest cat and five ADPKD cats with ~
15% FCV. Three cats with lower FCV had mildly low-
ered GFRs, which may be partially due to reduced renal
artery pressure secondary to the anesthesia. The age of
the cat cohort is relatively young (mean: 39.7 months
[range: 16.4–97.1 months]. Many human ADPKD pa-
tients have no obvious clinical symptoms until the third
or fourth decade of life [35] and renal function usually
remains normal until the fourth to sixth decade of life
[36]. A recent study of 377 cats from Japan indicated of
cats with the cat PKD1 mutation, the incidence of a high
concentration of plasma Cre (>1.6 mg/dl: ≥IRIS-CKD
stage 2) was greater in cats older than 3 years old, and
especially in those older than 7 years. In contrast, a few
cats aged ≥9 years had low plasma Cre concentrations
(≤1.6 mg/dl) [37]. Therefore, the correlation between
TKV and GFR may improve in older ADPKD cats.
TKV, rather than renal function, is suggested as the
more appropriate biomarker for monitoring and predict-
ing disease progression in human medicine [38]. In
humans, TKV measurements are obtained by MRI or
CT to assess the efficacy of therapeutic interventions
[23, 39, 40]. US, CT and MRI are all minimally invasive
and highly diagnostic for ADPKD in cats, with US being
the most rapid, least expensive, and most accessible.
MRI T2WI is sensitive and sufficient for volume meas-
urement and CT is associated with radiation exposure,
hence CT is less favored in human medicine [2, 40].
However, CT is favored in cats due to decreased
Fig. 2 FCV correlation with age in feline ADPKD. a The graph illustrates significant positive correlation between CT-based FCV and age amongst
11 ADPKD cats (solid line). One cat is a suggested outlier (bold dots). When excluding this cat, the correlation increases (dashed line). b The
graph demonstrates strong positive correlation between MRI-based FCV and age among eight ADPKD cats when the one outlier was excluded
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Table 4 Renal volumetric changes in cats with ADPKD
Volume Case Modality Initial Follow up Increase (ml) Increase/mo. (ml) Increase (%) Monthly increase (%) Initial FCV/mo Expected
increase
TKV Fast 3 CT 59.88 97.48 37.60 2.98 62.79 12.92
MRI 58.35 89.49 31.14 2.47 53.37 12.78
Slow 6 CT 57.33 83.52 26.19 1.75 45.68 9.71
MRI 62.85 64.36 1.51 0.10 2.40 6.83
TCV Fast 3 CT 12.63 30.36 17.73 1.41 140.43 19.08
MRI 20.92 42.87 21.95 1.74 104.92 17.08
Slow 6 CT 2.82 6.04 3.22 0.21 114.43 14.30
MRI 4.71 8.59 3.88 0.26 82.38 12.16
FCV Fast 3 CT 21.09 31.14 10.06 0.80 47.69 11.72 1.08 13.61
MRI 35.85 47.90 12.05 0.96 33.62 11.13 1.84 23.18
Slow 6 CT 4.91 7.23 2.32 0.15 47.19 9.81 0.10 1.5
MRI 7.49 13.35 5.85 0.39 78.10 11.87 0.16 2.4
Fig. 3 Longitudinal changes of imaging parameter using CT and MRI. Longitudinal changes were represented at the time of initial scan and
follow-up scan using CT (left figures) and MRI (right figures). Data of the fast progression cat were demonstrated with solid lines and data of slow
progression cat were demonstrated with broken lines. Note that increasing rate (slope) of FCV of two cats were similar in both CT and MRI
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anesthesia requirements and the minimal concern of
long-term consequences of radiation exposure.
US, CT and MRI were conducted in ADPKD cats to
estimate TKV. Normal cat kidney volumes have been es-
timated using water displacement at 18.99 ± 7.68 cm3,
and US and CT imaging from 14.8 ± 2.9 ml to 19.01 ±
7.55 ml, respectively [32, 41]. For ADPKD cats, total kid-
ney volumes have been estimated as 27.4 ± 10.3 ml using
US and 29.3 ± 13.4 ml by CT [32], ~ 30% larger than
normal cat kidneys. In this study, the 11 ADPKD cats
had kidney volume estimates from 23.0 ± 6.91 ml using
US to as high as 34.69 ± 6.36 ml using the planimetric
method for MRI thereby overlapping within normal
limits but also have significantly larger TKVs. Overall,
US and planimetry CT TKV estimates were slightly
smaller, however, within the ranges of previous study.
The cats in the previous study (mean age: 59 ± 10
months) [32] were an average of 20 months older than
this study (mean age: 39.67 ± 23.89 months), thus would
be expected to have larger TKVs. The TKV estimates for
a given cat were increasing larger over US-based TKV
estimates by 20, 22, 27, 34%, estimating by planimetry
CT, MIROS CT, MIROS MRI, and planimetry MRI, re-
spectively. The TKV for case 4 that was estimated by
water displacement was consistent with CT estimates,
but case 5 estimates were over-estimated by CT and
MRI, potentially due to the adipose tissue in this over-
weight cat.
In one study, cyst growth in humans is reported as
relatively symmetrically and at a steady rate [42]. How-
ever, other research has indicated variable expression of
cyst progression, even in the same family [43, 44]. In the
cats, FCVs were highly correlated with age, supporting
cyst size increasing with age and a steady rate. However,
Case 3 showed 1.08 and 1.84% increase in FCV per
month, by CT and MRI, respectively, which is approxi-
mately six times the average increase than the other
ADPKD cats. Once this “outlier” was removed from the
correlation analysis, FCV per month showed an average
of 0.19 and 0.29% by CT and MRI, respectively, and was
more highly correlated with age. Thus, for cats, most
cats have a consistent rate of disease progression, how-
ever, some cats are highly variability. Furthermore, the
value on TCV and FCV showed wide ranges as shown in
Table 3. Although ages were not uniform, these findings
also indicated that variability of cyst progression speed
among feline ADPKD cats, regardless of genetic homo-
geneity for the mutation. Feline ADPKD is individually
variable between kidneys of a given cat, even though all
cats had the same germline mutation (PKD1 c.10063C >
A), suggesting other factors modify disease expression
and progression.
Cats as a large animal model are clearly an asset to
evaluate the efficacy and safety of the development of
drugs and gene therapies [45, 46]. Although the exact
same mutation is not found in cats and humans, cats and
humans have similarly disruptive mutations that truncate
approximately 30% of polycystin-1. Feline ADPKD may fill
a void of translational research between rodent and hu-
man ADPKD. The rodent models do not perfectly recap-
itulate human ADPKD in terms of differences in lifespan,
metabolism, and renal anatomy [47]. Feline ADPKD has
the potential to overcome these differences. Although fe-
line ADPKD is caused by a single PKD1 c.10063C >A,
considering progression variability, disease progression of
feline ADPKD is likely influenced by other genetic and/or
environmental factors, such as those identified in humans
[48–51]. In addition, cats could support studies focusing
on pleiotrophic effects of ADPKD. A recent study showed
co-occurrence of hepatic and renal cysts was found in 20
(12.6%) out of 159 cat cases with renal cyst(s), and all
cases were positive for the PKD1mutation [37]. Identifica-
tion of genetic modifiers could lead to selection of appro-
priate cats with ADPKD for therapeutic trials and
reducing animal use and improving study design.
Conclusions
In conclusion, TKV, TCV, and FCV estimations are valu-
able for evaluating disease status of feline ADPKD and
could lead to renal failure risk classifications analogous
to humans [52, 53 ]. The current study shows imaging-
based estimations for TKV, TCV, FCV, and FCV per
month, can be easily determined for cats with ADPKD
using CT and MRI. While MRI is preferred to CT in hu-
man medicine due to radiation exposure, CT is more
practical to evaluate disease progression for feline
ADPKD because of rapid image acquisition that only re-
quires sedation or light anesthesia, lower cost, and in-
creasing availability. This study also demonstrates that
cystic progression is individual and variable in cats and
since cats have only on ADPKD variant and the genetic
model is highly similar to humans, cats should be useful
for studies focused on genetic modifiers and efficacy of
therapeutics.
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